Trial Profile
A trial to determine changes of lymphocyte counts (CD4 and CD8 T cells, B cells and their subtypes) in the peripheral blood of patients with multiple sclerosis treated for an extended period with fingolimod (MSFin) compared to healthy controls (HC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 04 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology